Milanda 3mg/0.03mg 21 tablets — Made in Spain — Free Delivery

Product description

Tablets "Milanda" are used for oral contraception.

Structure

One film-coated tablet contains (active ingredients):

• drospirenone - 3 mg;
• ethinylestradiol - 0.03 mg.

Excipients: lactose, monohydrate; corn starch; pregelatinized starch; crospovidone containing Plasdone XL-10 and Plasdon XL; povidone, polysorbate 80; magnesium stearate.

Film sheath: Opadray II yellow, which contains: polyvinyl alcohol, titanium dioxide (E 171), macrogol, talc, yellow iron oxide (E 172).

Contraindications

Combined hormonal contraceptives (CHCs) should not be used if at least one of the following conditions is present. If any of these conditions occurs for the first time during the use of CHC, the drug should be stopped immediately.

The presence or risk of developing venous thromboembolism (VTE):

• VTE at present, in particular due to anticoagulant therapy or a history (for example, deep vein thrombosis (DVT) or pulmonary embolism (PE));
• known hereditary or acquired tendency to VTE, such as resistance to activated protein C (including factor V Leiden mutation), antithrombin-III deficiency, protein C deficiency, protein S deficiency;
• major surgical interventions with prolonged immobilization;
• high risk of VTE due to the presence of multiple risk factors.

Presence or risk of developing arterial thromboembolism (ATE):

• current or history of ATE (eg myocardial infarction) or the presence of prodromal symptoms (eg angina pectoris);
• current or history of cerebrovascular accident, prodromal symptoms (eg, transient ischemic attack (TIA));
• a known hereditary or acquired tendency towards ATUs such as hyperhomocysteinemia and antibodies to phospholipids (eg antibodies to cardiolipins, lupus anticoagulant);
• migraine with a history of focal neurological symptoms;
• high risk of ATE due to the presence of multiple risk factors or due to the presence of one serious risk factor, such as:
• diabetes mellitus with vascular complications;
• severe arterial hypertension;
• severe dyslipoproteinemia.

A history of severe liver disease or a history of severe liver disease before liver function tests return to normal.

Severe renal failure or acute renal failure.

Current or history of liver tumors (benign or malignant).

Known or suspected malignant tumors (eg, genitals or mammary glands) that are sex hormone dependent.

Vaginal bleeding of unknown etiology.

Hypersensitivity to active substances or to any of the components of the drug.

Suspected or confirmed pregnancy.

Mode of application

Used internally. The tablets should be taken regularly at about the same time, with a small amount of liquid, if necessary, in the order indicated on the package. The drug is taken one tablet per day for 21 consecutive days. Taking pills from each next package should be started after the end of the 7-day break in taking the drug, during which withdrawal bleeding usually occurs. It usually starts 2-3 days after the last pill is taken and may not end until the next pack starts.

Application features

Children

The drug is indicated for use only after the onset of the first menstruation.

Drivers

There were no studies of the effect of the drug on the ability to drive vehicles or mechanisms. In women taking combined oral contraceptives, no effect on the ability to drive vehicles or operate machinery was reported.

Overdose

When using combined oral contraceptives, nausea, vomiting, or in young girls, vaginal bleeding is possible.

Treatment. Therapy is symptomatic. There is no specific antidote.

Side effects

Mental disorders: frequent (≥ 1/100 and <1/10) - depressed mood.

From the nervous system: frequent (≥ 1/100 and <1/10) - headache.

From the side of the vessels: frequent (≥ 1/100 and <1/10) - migraine.

From the gastrointestinal tract: frequent (≥ 1/100 and <1/10) - nausea.

From the reproductive system and mammary glands: frequent (≥ 1/100 and <1/10) - menstrual disorders, intermenstrual bleeding, breast tenderness, engorgement of the mammary glands, vaginal discharge, vulvovaginal candidiasis.

Storage conditions

Store in its original packaging at a temperature not exceeding 25 ° C, out of the reach of children.

Shelf life is 3 years.